Search for: "Allergan Inc" Results 1 - 20 of 297
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
16 Jan 2014, 9:41 pm by Patent Docs
Noonan -- If you have ever wondered how popular eyelash enhancers like RevitaLash and Latisse produce their effects, Allergan, Inc. v. [read post]
1 Aug 2019, 4:31 am
Jane Lambert Patents Court (Mr Justice Atnold)  Allergan, Inc and another v Aspire Pharma Ltd [2019] EWHC 1085 (Pat) (3 May 2019)  Allergan Inc is the proprietor of European patent EP1753434 for an enhanced bimatoprost ophthalmic solution which its English subsidiary, Allergan Ltd. exploits by marketing a product containing 0.1 mg/ml (0.01%) bimatoprost for ophthalmic [read post]
2 Sep 2014, 9:41 pm by Patent Docs
Allergan had asserted its 7,351,404 patent (the '404 patent) and Duke asserted its 7,388,029 patent (the '029 patent) after Apotex filed an ANDA for a generic version of Allergan's Latisse®, an ophthalmic solution comprising bimatoprost (a prostaglandin F-2-alpha ("PGF") analog) as the active ingredient. [read post]
13 Mar 2013, 8:34 am by Mandour & Associates
IPNews® - Allergan, Inc. was granted partial summary judgment against Cosmetic Alchemy, LLC for inducing its customers to infringe Allergan’s patents that cover its popular eyelash growth drug Latisse. [read post]
30 Jan 2013, 8:22 am by Mandour & Associates
Barr Laboratories, Inc. and Sandoz, Inc. were found by the lower court to not have sufficiently proven their claims that Allergan’s patent was invalid due to prior art and obviousness. [read post]
27 Oct 2009, 8:49 am
The United States District Court for the District of Delaware handed Allergan, Inc. [read post]
6 Apr 2016, 7:37 pm by Consuella Pachico
Pfizer Inc. and Allergan PLC withdrew their planned $160 billion merger, ending what would have been the largest so-called inversion transaction. [read post]
15 Aug 2014, 12:37 pm by Ray Frager
Rowe Price Group Inc., the Baltimore-based money manager, was among investors buying increased stakes in pharmaceutical company Allergan in the last quarter, according to Securities and Exchange Commission filings reported by Bloomberg News. [read post]
10 Nov 2014, 11:10 am by John Jascob
[This story previously appeared in Securities Regulation Daily.]By Anne Sherry, J.D.The Delaware Court of Chancery declined to issue declaratory relief blessing a hypothetical strategy by Allergan stockholders to replace the entire board at a special meeting, as the challenge to Allergan’s interpretation of the “similar item” provision in its governing documents was not ripe for review (In re Allergan, Inc. [read post]
9 Apr 2013, 7:23 am by Kristin Barlett
., holding that a derivative suit against Botox-maker Allergan, Inc. should be dismissed because Allergan had already secured a judgment in its favor in a nearly identical suit in California. [read post]
12 Apr 2007, 9:48 pm
By Donald Zuhn -- On Thursday, Allergan, Inc. announced that the U.S. [read post]
12 Aug 2015, 9:59 pm by Patent Docs
By Donald Zuhn -- In June, Allergan, Inc. and Allergan Sales, LLC filed suit against Ferrum Ferro Capital, LLC and Kevin Barnes ("FFC") in the U.S. [read post]
13 Jul 2015, 9:59 pm by Patent Docs
By Donald Zuhn -- Last month, Allergan, Inc. and Allergan Sales, LLC filed suit against Ferrum Ferro Capital, LLC and Kevin Barnes ("FFC") in the U.S. [read post]